AMPH vs. ADMA, PCVX, RYTM, CYTK, KRYS, AKRO, ZLAB, PTCT, RARE, and AAPG
Should you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include ADMA Biologics (ADMA), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Krystal Biotech (KRYS), Akero Therapeutics (AKRO), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.
Amphastar Pharmaceuticals vs. Its Competitors
ADMA Biologics (NASDAQ:ADMA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.
ADMA Biologics has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.
ADMA Biologics has higher earnings, but lower revenue than Amphastar Pharmaceuticals. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by company insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
ADMA Biologics has a net margin of 45.01% compared to Amphastar Pharmaceuticals' net margin of 19.38%. ADMA Biologics' return on equity of 47.16% beat Amphastar Pharmaceuticals' return on equity.
In the previous week, ADMA Biologics had 1 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 6 mentions for ADMA Biologics and 5 mentions for Amphastar Pharmaceuticals. ADMA Biologics' average media sentiment score of 1.27 beat Amphastar Pharmaceuticals' score of 0.23 indicating that ADMA Biologics is being referred to more favorably in the media.
ADMA Biologics currently has a consensus price target of $27.67, indicating a potential upside of 55.34%. Amphastar Pharmaceuticals has a consensus price target of $32.33, indicating a potential upside of 43.07%. Given ADMA Biologics' stronger consensus rating and higher probable upside, equities research analysts clearly believe ADMA Biologics is more favorable than Amphastar Pharmaceuticals.
Summary
ADMA Biologics beats Amphastar Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get Amphastar Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Amphastar Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AMPH) was last updated on 7/9/2025 by MarketBeat.com Staff